期刊文献+

重组蛋白药物电荷异质性的分析技术研究进展 被引量:3

Research Progress on Analytical Technique of Charge Heterogeneity of Recombinant Protein
原文传递
导出
摘要 电荷异质性是重组蛋白类药物的关键质量属性,对重组蛋白类药物的稳定性、溶解性、免疫原性、体内外生物学活性、药物动力学功能发挥具有重要的影响。选择一种灵敏度高、特异性强的电荷异质性检测分析方法,是控制和稳定重组蛋白药物生产质量的有效手段。该文章对电荷异质性的3种主要分析方法,即平板胶等电聚焦电泳、离子交换色谱、毛细管等电聚焦电泳等技术特点及近年的研究进展进行综述介绍。 Charge heterogeneity is a key quality attribute of recombinant protein drugs and has important influence on the stability,solubility,immunogenicity,biological activity in vitro and in vivo,and pharmacokinetic function of recombinant protein drugs. Selecting a high-sensitivity,high-specificity charge heterogeneity detection and analysis method is an effective means to control and stabilize the production quality of recombinant protein drugs. In this paper,the three main methods of charge heterogeneity are summarized,such as the electro-focusing electrophoresis of plate glue,ion exchange chromatography,and capillary isoelectric focusing electrophoresis,as well as the recent research progress.
作者 刘娴 茹莉莉 杨大军 吴京雷 LIU Xian;RU Li-li;YANG Da-jun;WU Jing-lei(Beijing Tri-Prime Gene Pharmaceutical Co.,Ltd.,Beijing 102600,China)
出处 《药物生物技术》 CAS 2018年第5期461-466,共6页 Pharmaceutical Biotechnology
关键词 电荷异质性 重组蛋白 平板胶等电聚焦电泳 离子交换色谱 毛细管等电聚焦电泳 Charge heterogeneity Recombinant protein Plate adhesive isoelectric focusing electrophoresis Ion exchange chromatog-raphy Capillary isoelectrie focusing electrophoresis
  • 相关文献

参考文献7

二级参考文献59

  • 1Sheng Lia,1, Hao Wangb,1, Baozhen Penga, Meilan Zhanga, Daipong Zhangb, Sheng Houb, Yajun Guob,2, and Jianping Dinga,2 aState Key Laboratory of Molecular Biology and Research Center for Structural Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yue-Yang Road, Shanghai 200031, China,bInternational Joint Cancer Institute, Second Military Medical University, 800 Xiang-Yin Road, Shanghai 200433, China 1These authors contributed equally to this work..Efalizumab binding to the LFA-1 α_L I domain blocks ICAM-1 binding via steric hindrance[J].生物物理学报,2009,25(S1):342-342. 被引量:1
  • 2K6hler G, Milstein C. Continuous culture of fused cells secreting antibody d predefined specificity[J]. Nature, 1975, 256 (5517): 495-497.
  • 3Demarest S J, Glaser SM. Antibody therapeutics, antibody engineer- ing, and the merits of protein stability[J]. Curr Opin Drug Diseov Bevel, 2008, 11 (5) : 675-687.
  • 4Schneider CK. Monoclonal antibodies--regulatory challenges [J]. Curr Phann Biotechnol, 2008, 9 (6) : 431-438.
  • 5Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody[J]. Nature, 1984, 312(5995): 643 -646.
  • 6Siddiqui MZ. Monoelonal antibodies as diagnostics :" an appraisal [J]. Indian J Pharm Sci, 2010, 72( 1 ) : 12-17.
  • 7Nakano K, Ishiguro T, Konishi H, et-al. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization [J]. Antieaneer Drugs, 2010, 21 (10) : 907-916.
  • 8Harding FA, Stickler MM, Razo J, et al. The immunogenicity of hu- manized and fully human antibodies: residual immunogenicity re- sides in the CDR regions[J]. MAbs, 2010, 2(3) : 256-265.
  • 9Kashmiri SV, De Pascalis R, Gonzales NR, et al. SDR grafting--a new approach to antibody humanization[J]. Methods, 2005, 36 (1) : 25-34.
  • 10Sehlin D, Hedlund M, Lord A, et al. Heavy-chain complementarity-determining regions determine conformation selectivity of anti-otl3 antibodies[J]. Neurodegener Dis, 2011, 8(3): 117-123.

共引文献33

同被引文献15

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部